univers coverag
calendar event
reimburs review data releas payer psychiatrist edt
medacorp puls call anti-trust outlook vertic mega-merg pbms/
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medic meet american associ immunologist american associ
orthodontist american psychiatr associ pan american societi
bottom line luxturna price final grow number gene therapi
clinic spoke medacorp payor conduct analysi better estim price
hemophilia gene therapi industri pipelin result work rais assum
price hemophilia gene therapi coverag univers per patient increas prior
assumpt per patient estim program earlier develop
check indic may headroom potenti per patient
gross basi given uncertainti respons rebat factor believ
reason estim net price per patient junctur believ manufactur
test water current embark phase trial order determin payor push
back significantli base check price somewher rang per patient seem
despit approv specif ultra-rar blind disord luxturna price per eye set
use preced futur gene therapi therapeut categori hemophilia believ
appli harvard pilgrim framework direct medic cost believ price least
per patient hemophilia gene therapi justifi
estim current hemophilia gene therapi pipelin candid collect
month worth durabl data time come market thu justifi price
 methodolog sum-of-the-part dcf discount rate pipelin
bottom line base discuss medacorp payor specialist link
updat revenu estim reflect new price assumpt valrox hemophilia
chang estim increas pt previous reiter op
increas price assumpt valrox us/eu
studi on-going biomarin lead hemophilia
assum market entri culmin peak sale
updat hemophilia price assumpt ad pomp program pt
 methodolog dcf discount rate termin growth rate
bottom line accord hemophilia price note link adjust price
assumpt spark hemophilia gene therapi hemophilia
respect also luxturna avail commerci inherit retin dystrophi due
biallel mutat gene adjust discount termin growth rate
compani combin pt increas previous reiter mp
hemophilia program particularli hemophilia remain import driver valuat
next updat import
sale spark receiv peak
royalti latter
chang discount termin growth rate increas pt
revenu mm ep
updat model higher price assumpt po
pt
 methodolog discount dcf discount rate
bottom line base discuss medacorp payor specialist link rais
price estim hemophilia per patient us eu
respect also increas probabl success huntington disease/
hd vs previous incorpor compani financi result chang
estim increas pt previous reiter op qure
assumpt reflect potenti lead hemophilia
project peak sale
transit like astut could pose residu clinic
increasingli optimist ahead ind file subsequ entri clinic
po increas
revenu present mm ep
clear align competit updat dentspli schein
ep growth impli price-to-earnings ep cash
bottom line expect on-going american associ orthodontist
confer -- washington dc -- -there clear align launch announc
sever new entrant includ dentspli announc fri
link although step-up clear align competit expect believ prove
market expansionari long run could volatil near-to-intermedi term rise
competit natur rais question potenti futur price pressur share shift competit
trial impact etc -- consider wont figur out/resolv overhang
overnight far base weve seen/heard still inclin view competit
relat pullback buy opportun one attract growth stori med-tech
need work come qtr truli understand increas competit
clear align segment may may impact algn growth prospect
light believ signific anxiety/anticip competit launch
would highlight sever area may actual prove
sotp suggest pipelin free even stock bounc
averag dcf price-to-earnings p/sale
bottom line stock declin near past three month outpac
biotech broader market indic declin low-mid singl digit percentag
period prompt review perform sum-of-the-part sotp analysi
base judgement stock might becom interest given progress
portfolio recent stock price sotp-bas fair valu analysi highlight note suggest
biogen multipl sclerosi ms biosimilar portfolio addit spinraza aducanumab risk
adjust rituxan/gazyva/ocrevu royalti stream cash worth approxim use
standard industri valuat metric close current price target test
analysi duplic valuat exercis use consensu revenu forecast also use publicli
avail compar valuat basi yield similar result valuat base
individu product cash flow npv estim sotp fair valu
recent close price valuat discrep larg driven neg sentiment
outlook compani core ms busi competit threat spinraza franchis
concern whether aducanumab ever realiz valu
assess downsid potenti disappoint around two main investor controversi
repeat analysi use pessimist assumpt likelihood aducanumab
approv long-term growth outlook spinraza
plazomicin valu still intact updat valuat methodolog pt
dcf analysi discount rate termin growth rate
bottom line friday akao announc earn lp
consensu estim recent adcom result link street expect plazomicin
soon approv cuti indic june pdufa debat shift
fda view bloodstream infect bsi data context adcom vote believ
high likelihood microbiolog data includ label support use
bsi much like saw allergan op avycaz plazomicin good addit physician
armamentarium differenti mechan beta-lactams/beta-lactamas inhibitor bl/bli
treat still view launch trajectori avycaz fair comp plazomicin figur
view plazomicin differenti competit profil figur howev take slightli
cautiou approach initi uptak given uncertainti around whether data
dose adjust bsi label believ physician still use bl/bli ahead
aminoglycosid given comfort level class akao also delay initi
phase pivot c-scape cite conduct addit phase clinic
pharmacolog studi optim likelihood clinic commerci success
includ c-scape model po final updat valuat methodolog
akao shift dcf valuat mix dcf/revenu multipl taken togeth
chang lower pt dcf base valuat impli revenu multipl
stock high end rang recent transact within anti-infect space
reason view given downward pressur valuat anti-infect space
recent month believ current level street underappreci valu plazomicin
assign minim valu c-scape manag execut launch post approv
see momentum stock fda decis pdufa date bsi indic
better model could upsid rang figur
plazomicin cuti continu believ drive sale
plazomicin bsi reiter sale believ reflect
conserv outcom pdufa date take slightli cautiou approach
c-scape includ risk-adjust sale model po base
proven efficaci individu compon
akao plazomicin pdufa data june akao also plan submit ema
small step right direct bullish tone back perform
 methodolog averag method dcf price earn price sale
bottom line celgen may announc result modest beat revenu
pro forma ep compar consensu signific delay time two import
develop program connect ozanimod multipl sclerosi ms program re-fil
postpon hope time full enrol pivot trial
ulcer coliti uc postpon oper perform
compani boost slight channel inventori build well currenc
effect overal see littl get terribl excit near term perhap
chang compani manag structur appoint industry-experienc
profession board senior manag team compani base quarter
result disclosur commentari decreas target price maintain
outperform rate given valu compani exist product tangibl late stage
pipelin total revenu consensu adjust dilut ep came
consensu expect ep beat primarili driven
activ share buy-back celgen expect resubmit nda ozanimod
year later initi submiss interestingli market respons larg favor
investor appear reliev news time wasnt wors believ stock
reach less floor valuat investor low expect compani
modest revenu beat somewhat encourag given histor weak celgen
due season investor probabl price even wors scenario ozanimod
recent specul delay approv think new timelin ozanimod re-fil
still mean face uphil battl gener gilenya combin uncertainti
profil previous uncharacter metabolit continu overhang
program valu celgen stock trade valuat assum contribut
revlimid contribut either ozanimod luspatercept link believ
stock remain under-valued overlook nevertheless decreas target price
maintain outperform rate
revenu million ep exclud option expens
ev/ebitda adj ebitda mm
bottom line reiter op rate cotv challeng pca larg driven
certain client specif issu rca continu strong growth momentum compani
report modest miss adj ebitda adj ep in-lin modest miss larg
driven weak pca busi issu quarter pca one-tim client
specif natur scope expans cross-sel implement recent win volum
increas start drive pca revenu growth rca continu strong growth momentum
top-line grow yoy adj ebitda guidanc maintain top-line guidanc
narrow maintain adj ebitda estim mm lower revenu
estim mm ex one-tim adjust mid-point guidanc rang
modestli lower adj ebitda estim mm mm revenu estim
mm mm revenu estim contempl low doubl digit growth balanc sheet solid
leverag decreas end end equival
parent mm pt contempl ev ebitda
modest miss adj ebitda in-lin adj ep
adj ebitda guidanc maintain mm
maintain adj ebitda estim
manag upbeat pca growth outlook rca carri forward growth momentum
rowdmap integr track valu asset expect exceed initi estim
balanc sheet solid
pt contempl ev/ebitda adjust ebitda mm
revenu mm use adj ep number may add total due round
recap pipelin track asco pt
 methodolog dcf analysi revenu multipl dr tgr
bottom line report financi result provid pipelin updat consist
prior guidanc recal compani lead proprietari product candid mirvetuximab soravtansin
current phase develop forward-i single-ag platinum-resist ovarian
cancer addit on-going forward-ii phase i/ii studi evalu drug combin
avastin keytruda carboplatin/avastin advanced/metastat ovarian cancer recent success
complet interim analysi phase forward studi mirvetuximab soravtansin
platinum-resist ovarian cancer link increment posit sever import catalyst
next month provid good setup stock view phase ii dose-expans data
forward-ii trial expect american societi clinic oncolog
annual meet avastin combin european societi medic oncolog esmo cancer
candid partner repres sourc upsid view
next clinic updat expect late year american societi hematolog annual
forward phase platinum-resist ovarian cancer on-going top-lin still expect
mirvetuximab forward-ii combin studi ovarian cancer set multipl readout year
phase studi acut myeloid leukemia
end cash cash equival suffici fund oper
previous guid
revenu million ep fiscal year chang june dec
bottom line maintain mp rate rais pt lpnt report
line revenu ebitda exceed buysid expect price growth driven higher acuiti
improv commerci medicar rate along product improv across portfolio
scrutin asset class off-set continu volum soft guidanc maintain
stock ralli nice question go foward guidanc achiev particularli flat
slightli volum manag explan soft larg result one fewer day
quarter acuiti allow price growth remain key off-set appear
upsid swb salari wage benefit margin year like best
guid manag also expect increment free cash flow fuel invest ambulatori
access point given elev capital-expenditure across marquett maintain
ebitda mm midpoint guidanc lower ebitda mm
consensu assum bp margin expans bp previous
line revenu ebitda exceed buysid expect
lpnt guid flat slightli volum comp eas throughout year challeng remain
shift lesser acuiti procedur outpati ambulatori
price strong favor commerci medicar rate increas acuiti tailwind
season expect normal throughout year
progress strateg review cost manag swb improv qoq yoy
chang guidanc
chang ebitda
capital-expenditure expect acceler turn posit
rais pt
enter clear align market
bottom line morn announc introduct new clear align
system american associ orthodontist confer washington
new slx clear align system incorpor sagitt first/mot technolog
orthodont busi compani expect reduc number align
need use typic case compar current product market expand
product market align system reli open sourc platform
accept stereolithographi digit impress lead intraor scanner accord
press releas sound like align system abl handl problem requir
extens correct work well simpl aesthet problem announc
enter field current domin op may see addit
compet product announc on-going american associ orthodontist
confer run
recap earli day makena sq still gener im intrarosa
bottom line recent win fda ferahem ferumoxytol link makena
hydroxyprogesteron caproat link posit step though sale
makena lower our/street estim -- like due season
effect -- repres yoy increas though posit top line may miss
opportun maxim revenu current market share futur gener
enter market time possibl erod posit furthermor despit recent
label expans ferahem non-chron kidney diseas ckd pt iron defici
anemia compani report decreas yoy sale attribut salin
shortag necessari compon intraven infus ferahem therefor remain
seen recent expand label add top line posit note
revenu intrarosa prasteron -- indic postmenopaus women moderate-to-sever
dyspareunia -- continu increas beat our/street estim
lastli compani await fda decis recent submit nda rekynda
bremelanotid hypoact sexual desir disord hsdd product think add
top line updat model incorpor financi result well
adjust project concord compani updat guidanc reiter
mp
revenu present mm non-gaap ep non-gaap ep calcul analyst
 guidanc rais gm shld pt
 methodolog pro forma w/bcr ep
bottom line deliv rev/ep ahead consensu first qtr
bcr belt sale out-performance favor fx prompt management increas
bd newco rev/ep guidanc result leav us confid bdx/bcr newco
abil deliv org cc top-lin growth mid-teen dd ep growth next year
bcr integr unfold management increas newco guidanc cc revenue growth
cc ep growth captur street near midpoint revenue ep continu
posit regard ep step-up bcr transact provid context
volatil market may view rel safer invest potenti limit stock downsid
pt vs prior assum trade premium large-cap med-tech diversifi
peer given above-averag ep growth potenti get construct name like greater
convict upsid bcr synergi forecast order argu bigger multipl premium large-cap
med-tech diversifi vs current ascrib turn price-to-earnings premium ep
vs group reiter mp
bd stand-alone onward new co inclus bcr oper deal close
sale
bottom line ivti revenue y/i in-lin management reiter
excess revenue outlook stock trade share ytd think
expect low print fear factor miss stick op
rate believ current depress stock level valuat disconnect compani
long-term growth profil compani hit exceed forecast
continu drive dispos revenu growth key baromet lt health busi
view believ stock worth least use ev/sal
multipl end day ivti dd top-lin grower beyond ivti
show-m stori could take sever qtr improv execut re-instil investor confid
believ risk-reward skew upsid given view ivti portfolio could offer strateg
valu larger medic devic compani call point multipl call point across gen surgeri
orthoped gyn plastic surgeri potenti provid downsid protect
revenu million
bottom line report provid updat week end april key gener
product watch
weekli iqvia im trend week end april
adopt momentum continu drive out-performance runway long
pt
 methodolog ev/sal multipl estim
dcf valuat use discount rate lt growth rate
start year instal time hold back nmr pickup
cordi woe unlik spread guid clear event pt
 methodolog ep
strong fear pbm biz model overblown sharehold vote posit
ep
revenu earn start year
blend revenu multipl dcf analysi discount rate termin growth
book steadi market remain highli competit
stannsoporfin hit roadblock fda adcom consist
use wacc termin growth rate
rais solid like enough derail lt growth
 methodolog sale
 methodolog averag price-to-earnings p/ dcf methodolog
recap eteplirsen paus ema pipelin base biz intact pt
qtr still limit visibl longer term sale growth driver
ev/ebitda multipl
ep
hcit distribut transit analyt value-bas continu
healthcar distribut volum price look suppli chain preview
healthcar facil in-line posit catalyst would
also posit
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
may dova pdufa avathombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
may pdufa peg-pal pegvalias phenylketonuria pku
management remain optimist posit outcom fda convey
peg-pal pku shown lower blood phenylalanin amino acid accumul
pt phase studi
think neurocognit data requir fda registr base
discuss agenc
initi induction/titr phase like translat lower revenu per patient
management note meaning reduct phe consequ well ast
adult pt popul could lead attract market opportun almost sale
price releas upon approv management guid modest premium
ahead may pdufa management appear cautiou potenti launch
highlight lower dose use initi lower revenu per pt pegvalias
revenu may limit downsid impact revenu guidanc
yet pku clinic alreadi experienc pegvalias via clinic trial initi
physician pt feedback presum could help investor better project pku
june american societi clinic oncolog
year meet updat patient treat combin
lead candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
view agent novel chemic structur avoid format presum toxic
metabolit good reason atogep could avoid liver toxic seen
telcagep follow-on compound
support view gen molecul calcitonin gene-rel peptid cgrp
may avoid liver safeti risk management report un-blind look liver enzym
elev agn on-going atogep studi line placebo event rate
clinic studi
atogep deliv efficaci profil within strike distanc inject
good safeti toler work suggest sizabl market opportun base
inject categori oral late entrant xeljanz rheumatoid arthriti otezla
psoriasi
believ program good chanc success view success
atogep migrain prevent would offer signific valid agn open-sci
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therapi confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
scph lead asset furoscix at-hom diuresi anticip pdufa action date
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
sourc leerink research compani inform factset price prior day
fda adcom endocrinolog metabol drug
fda jtn adcom pediatr endocrinolog metabol drug
fda adcom vaccin relat biolog product
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
fda adcom joint anesthet analges drug product drug safeti
fda adcom anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
american associ immunologist
american associ orthodontist
pan american societi clinic virolog
european societi pediatr gastroenterolog hepatolog nutrit
societi biolog psychiatri
societi pediatr radiolog
abstract releas edt
societi investig dermatolog
american societi gene cell therapi
american associ clinic endocrinologist updat afirma
societi neurolog surgeon
world feder hemophilia link
european academi allergi clinic immunolog
american societi clinic psychopharmacolog
american colleg sport medicin
european feder nation associ orthopaed traumatolog
societi imag informat medicin
american societi clinic oncolog
american societi transplant surgeon
american societi neuroradiolog
american societi mass spectrometri
uk take-over code may make decis respect
potenti bid shire
model model teva model model univers coverag
hcit distribut transit analyt value-bas continu
healthcar distribut volum price look suppli chain preview
healthcar facil in-line posit catalyst would
also posit
 like posit catalyst conserv guidanc
medic suppli devic individu co preview ortho supplies/cap equipment/
medic suppli devic individu co preview cardio large-cap diversifi
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash highlight invokana fda warn puls call modest impact
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
biopharma -- flash highlight invokana fda warn puls call modest impact
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma name shame california latest strategi rein drug price
healthcar distribut suppli chain preview price volum trend appear
hcit distribut outlin possibl drug price polici draconian
fear
 elast demand consist reduc price drive volum growth
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
achn recap increment advanc patent complement progress
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
